Celladon Corp (CLDN) 13.59 $CLDN
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 22, 5:13PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HTBX: 7.71 (-0.64), APTO: 5.94 (-0.53), ALDX: 9.30 (-1.45), ASMB: 16.78 (-2.76), CLDN: 13.59 (-2.77), APS.TO: 7.25 (-0.65), ADTN: 16.61 (-1.92), CREE: 32.36 (-3.04)
First Week of CLDN December 18th Options Trading
StockOptionsChannel.com - Wed Apr 22, 10:38AM CDT
Investors in Celladon Corp saw new options become available this week, for the December 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the...
CLDN: 13.59 (-2.77)
Celladon trends lower on bearish article
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 9:23AM CDT
CLDN: 13.59 (-2.77)
Celladon: CUPID-2 Is Likely To Fail
Blair O'Neill - Seeking Alpha - Wed Apr 22, 8:21AM CDT
Much has been said among analysts ( here and here ), and Seeking Alpha authors ( here and here ), about Celladon's (NASDAQ: CLDN ) MYDICAR's monumental upside if the upcoming Phase 2 trial results are positive. However, very little has been said...
CLDN: 13.59 (-2.77)
Is Legalized Marijuana or Gene Therapy the Better Emerging Industry?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:59AM CDT
The ability to spot powerful new technologies or industries early on can result in eye-popping returns for investors. The brave few that initially recognized the potential of Tesla Motors ' electric car, for example, have been richly rewarded over...
BLUE: 136.49 (+1.22), TSLA: 219.44 (+10.03), QURE: 26.15 (-1.44), GWPH: 113.04 (-0.05), CLDN: 13.59 (-2.77)
Celladon: A Good Deal, And A Rare Buy-Write Opportunity
Jason Ditz - at Seeking Alpha - Mon Apr 20, 7:25AM CDT
CLDN: 13.59 (-2.77)
Cardiomyopathy Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 15, 1:20PM CDT
The report "Cardiomyopathy - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Cardiomyopathy. Cardiomyopathy, any cardiac disease process that results in heart failure due to a decrease in the pumping power of the heart or due to an impairment in the filling of the cardiac chambers. Types of Cardiomyopathy are ischemic, dilated, hypertrophic and restrictive Cardiomyopathy. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cardiomyopat...eport.html .
GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), CLDN: 13.59 (-2.77), NVS: 103.45 (-0.62)
Celladon (CLDN) Shows Strength: Stock Moves Up 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 7:51AM CDT
Celladon Corporation (CLDN) was a big mover last session, as its shares rose almost 10% on the day.
CLDN: 13.59 (-2.77), AFFX: 12.57 (-0.13)
2 Speculative Biotechs That Could Be Well Worth the Risk
George Budwell, The Motley Fool - Motley Fool - Tue Apr 14, 5:59AM CDT
Biotech stocks can produce stunning returns in short order, especially clinical-stage companies working on game-changing drugs or medical devices. These stocks are some of the riskier types of assets, though, frequently plummeting on negative...
QURE: 26.15 (-1.44), PFE: 34.93 (+0.04), CLDN: 13.59 (-2.77), BMY: 66.60 (-0.21), EIDO: 27.75 (+0.22), EXEL: 3.12 (+0.05)
UniQure Deal Confirms Red-Hot Interest In Advanced Therapies
EP Vantage - at Seeking Alpha - Tue Apr 07, 3:42PM CDT
If there is any sign that pharma is beating the bushes to flush out promising advanced therapies, it is that Bristol-Myers Squibb (NYSE: BMY ) has shelled out $50m to license a preclinical gene therapy project that UniQure (NASDAQ: QURE ) ...
BLUE: 136.49 (+1.22), CLDN: 13.59 (-2.77), BMY: 66.60 (-0.21)
Why uniQure N.V. Stock Skyrocketed Today
George Budwell, The Motley Fool - Motley Fool - Mon Apr 06, 9:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the Dutch gene-therapy company uniQure ...
BLUE: 136.49 (+1.22), JNJ: 100.43 (+0.13), QURE: 26.15 (-1.44), PFE: 34.93 (+0.04), CLDN: 13.59 (-2.77), BMY: 66.60 (-0.21), NVS: 103.45 (-0.62)
3 Events That Could Sink the Biotech Sector This Year
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Apr 05, 8:06AM CDT
The biotech sector has been hot over the last few years, which naturally leads to talk of a biotech bubble. We asked our healthcare experts for potential events that might pop that bubble -- or at least let a little air out. While we're certainly...
BLUE: 136.49 (+1.22), IMS: 27.73 (+0.04), ESRX: 86.12 (+0.02), GILD: 104.18 (-1.02), CLDN: 13.59 (-2.77), ABBV: 64.52 (+0.91)
Has the Biotech Bubble Already Popped?
George Budwell, The Motley Fool - Motley Fool - Sat Apr 04, 8:59AM CDT
During the last couple of years, it seemed that you could pick almost any biotech stock and end up making jaw-dropping gains. The Nasdaq Biotech Index , for instance, has nearly tripled in value since 2010: This parabolic rise has generated...
DVAX: 23.41 (-0.07), INO: 10.39 (-0.09), BIIB: 423.57 (+1.46), GILD: 104.18 (-1.02), ARWR: 6.88 (+0.14), SRPT: 13.52 (+0.04), IBB: 363.84 (-0.66), CLDN: 13.59 (-2.77), CELG: 115.54 (+0.72)
Why Shares in Celladon Corp Burst Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 31, 12:28PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Celladon Corp dropped by as...
CLDN: 13.59 (-2.77)
Celladon's (CLDN) CEO Krisztina Zsebo on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 31, 9:18AM CDT
CLDN: 13.59 (-2.77)
Celladon reports 4Q loss
Automated Insights - Tue Mar 31, 9:01AM CDT
SAN DIEGO (AP) _ Celladon Corp. (CLDN) on Tuesday reported a loss of $11.3 million in its fourth quarter.
CLDN: 13.59 (-2.77)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 8:13AM CDT
GV: 1.67 (-0.04), CANF: 2.12 (+0.17), SNTA: 2.97 (+0.01), BCRX: 10.62 (-0.09), GBSN: 4.98 (+1.44), TCK: 12.87 (-0.03), CHTR: 184.88 (-1.93), DANG: 8.96 (+0.06), CLDN: 13.59 (-2.77), REXX: 4.77 (-0.04), MOV: 30.62 (-0.18)
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 22, 5:13PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HTBX: 7.71 (-0.64), APTO: 5.94 (-0.53), ALDX: 9.30 (-1.45), ASMB: 16.78 (-2.76), CLDN: 13.59 (-2.77), APS.TO: 7.25 (-0.65), ADTN: 16.61 (-1.92), CREE: 32.36 (-3.04)
First Week of CLDN December 18th Options Trading
StockOptionsChannel.com - Wed Apr 22, 10:38AM CDT
Investors in Celladon Corp saw new options become available this week, for the December 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the...
CLDN: 13.59 (-2.77)
Celladon trends lower on bearish article
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 9:23AM CDT
CLDN: 13.59 (-2.77)
Celladon: CUPID-2 Is Likely To Fail
Blair O'Neill - Seeking Alpha - Wed Apr 22, 8:21AM CDT
Much has been said among analysts ( here and here ), and Seeking Alpha authors ( here and here ), about Celladon's (NASDAQ: CLDN ) MYDICAR's monumental upside if the upcoming Phase 2 trial results are positive. However, very little has been said...
CLDN: 13.59 (-2.77)
Is Legalized Marijuana or Gene Therapy the Better Emerging Industry?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:59AM CDT
The ability to spot powerful new technologies or industries early on can result in eye-popping returns for investors. The brave few that initially recognized the potential of Tesla Motors ' electric car, for example, have been richly rewarded over...
BLUE: 136.49 (+1.22), TSLA: 219.44 (+10.03), QURE: 26.15 (-1.44), GWPH: 113.04 (-0.05), CLDN: 13.59 (-2.77)
Celladon: A Good Deal, And A Rare Buy-Write Opportunity
Jason Ditz - at Seeking Alpha - Mon Apr 20, 7:25AM CDT
CLDN: 13.59 (-2.77)
Cardiomyopathy Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 15, 1:20PM CDT
The report "Cardiomyopathy - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Cardiomyopathy. Cardiomyopathy, any cardiac disease process that results in heart failure due to a decrease in the pumping power of the heart or due to an impairment in the filling of the cardiac chambers. Types of Cardiomyopathy are ischemic, dilated, hypertrophic and restrictive Cardiomyopathy. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cardiomyopat...eport.html .
GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), CLDN: 13.59 (-2.77), NVS: 103.45 (-0.62)
Celladon (CLDN) Shows Strength: Stock Moves Up 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 7:51AM CDT
Celladon Corporation (CLDN) was a big mover last session, as its shares rose almost 10% on the day.
CLDN: 13.59 (-2.77), AFFX: 12.57 (-0.13)
2 Speculative Biotechs That Could Be Well Worth the Risk
George Budwell, The Motley Fool - Motley Fool - Tue Apr 14, 5:59AM CDT
Biotech stocks can produce stunning returns in short order, especially clinical-stage companies working on game-changing drugs or medical devices. These stocks are some of the riskier types of assets, though, frequently plummeting on negative...
QURE: 26.15 (-1.44), PFE: 34.93 (+0.04), CLDN: 13.59 (-2.77), BMY: 66.60 (-0.21), EIDO: 27.75 (+0.22), EXEL: 3.12 (+0.05)
UniQure Deal Confirms Red-Hot Interest In Advanced Therapies
EP Vantage - at Seeking Alpha - Tue Apr 07, 3:42PM CDT
If there is any sign that pharma is beating the bushes to flush out promising advanced therapies, it is that Bristol-Myers Squibb (NYSE: BMY ) has shelled out $50m to license a preclinical gene therapy project that UniQure (NASDAQ: QURE ) ...
BLUE: 136.49 (+1.22), CLDN: 13.59 (-2.77), BMY: 66.60 (-0.21)
Why uniQure N.V. Stock Skyrocketed Today
George Budwell, The Motley Fool - Motley Fool - Mon Apr 06, 9:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the Dutch gene-therapy company uniQure ...
BLUE: 136.49 (+1.22), JNJ: 100.43 (+0.13), QURE: 26.15 (-1.44), PFE: 34.93 (+0.04), CLDN: 13.59 (-2.77), BMY: 66.60 (-0.21), NVS: 103.45 (-0.62)
3 Events That Could Sink the Biotech Sector This Year
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Apr 05, 8:06AM CDT
The biotech sector has been hot over the last few years, which naturally leads to talk of a biotech bubble. We asked our healthcare experts for potential events that might pop that bubble -- or at least let a little air out. While we're certainly...
BLUE: 136.49 (+1.22), IMS: 27.73 (+0.04), ESRX: 86.12 (+0.02), GILD: 104.18 (-1.02), CLDN: 13.59 (-2.77), ABBV: 64.52 (+0.91)
Has the Biotech Bubble Already Popped?
George Budwell, The Motley Fool - Motley Fool - Sat Apr 04, 8:59AM CDT
During the last couple of years, it seemed that you could pick almost any biotech stock and end up making jaw-dropping gains. The Nasdaq Biotech Index , for instance, has nearly tripled in value since 2010: This parabolic rise has generated...
DVAX: 23.41 (-0.07), INO: 10.39 (-0.09), BIIB: 423.57 (+1.46), GILD: 104.18 (-1.02), ARWR: 6.88 (+0.14), SRPT: 13.52 (+0.04), IBB: 363.84 (-0.66), CLDN: 13.59 (-2.77), CELG: 115.54 (+0.72)
Why Shares in Celladon Corp Burst Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 31, 12:28PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Celladon Corp dropped by as...
CLDN: 13.59 (-2.77)
Celladon's (CLDN) CEO Krisztina Zsebo on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 31, 9:18AM CDT
CLDN: 13.59 (-2.77)
Celladon reports 4Q loss
Automated Insights - Tue Mar 31, 9:01AM CDT
SAN DIEGO (AP) _ Celladon Corp. (CLDN) on Tuesday reported a loss of $11.3 million in its fourth quarter.
CLDN: 13.59 (-2.77)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 8:13AM CDT
GV: 1.67 (-0.04), CANF: 2.12 (+0.17), SNTA: 2.97 (+0.01), BCRX: 10.62 (-0.09), GBSN: 4.98 (+1.44), TCK: 12.87 (-0.03), CHTR: 184.88 (-1.93), DANG: 8.96 (+0.06), CLDN: 13.59 (-2.77), REXX: 4.77 (-0.04), MOV: 30.62 (-0.18)
